US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchison Medi Pharma
Hutchmed Europe B.V.
Hutchison Medi Pharma drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shanghai, CN HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 6
- Programs
- 4
- Drugs
- 6
- Patents
- 0
Hutchison Medi Pharma pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hutchison Medi Pharma drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP], mitochondrial.
- Target
- Isocitrate dehydrogenase [NADP], mitochondrial
- Mechanism
- Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Hutchison Medi Pharma in public FDA and regional records.
-
Development asset linked to Hutchison Medi Pharma in public FDA and regional records.
-
Development asset linked to Hutchison Medi Pharma in public FDA and regional records.